Psychedelic Research in
Greece
Blossom currently tracks 5 psychedelic clinical trials connected to Greece, including 2 active studies. The country page also links to 3 stakeholders, giving the page ecosystem context beyond registered studies.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Greece.
- 1
Blossom tracks 5 psychedelic clinical trials connected to Greece, including 2 active studies.
- 2
Visible trial compounds include Esketamine, Ketamine and Psilocybin.
- 3
Visible trial topics include Major Depressive Disorder (MDD), Chronic Pain and Treatment-Resistant Depression (TRD).
- 4
The country page links to 3 stakeholders in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research Snapshot
Blossom currently tracks 5 psychedelic clinical trials connected to Greece, including 2 active studies.
- Active trials
- 2
- Total trials
- 5
- Stakeholders
- 4
- Events
- 0
Currently active in Blossom
Country-linked records
Linked organisations
No linked events
Top Compounds
- Esketamine(3)
- Ketamine(2)
- Psilocybin(1)
Top Study Topics
- Major Depressive Disorder (MDD)(3)
- Chronic Pain(1)
- Treatment-Resistant Depression (TRD)(1)
Active Trial Preview
View all trials →- A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder (EMBRACE)Recruiting - III
- The Effect of a Four Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (INTENSIFY MDD)Recruiting - III
Medical Access Snapshot
Greece maintains a restrictive controlled-substances regime under Law 4139/2013; licensed pharmaceutical psychedelics that have EU marketing authorisations (currently esketamine/Spravato) are available under tight clinical controls, but routine public reimbursement and broad medical access for classic psychedelics (psilocybin, MDMA, DMT, etc.) do not exist outside approved clinical research. Off-label clinical use of ketamine for anesthesia and some private off-label psychiatric uses occurs, but most other compounds remain scheduled with no authorized...
Regulatory Status
The linked medical access and reimbursement guide summarises Greece as "Medical Only (Private)". Greece maintains a restrictive controlled-substances regime under Law 4139/2013; licensed pharmaceutical psychedelics that have EU marketing authorisations (currently esketamine/Spravato) are available under tight clinical controls, but routine public reimbursement and broad medical access for classic psychedelics (psilocybin, MDMA, DMT, etc.) do not exist outside approved clinical research. Off-label clinical use of ketamine for anesthesia and some private off-label psychiatric uses occurs, but most other compounds remain scheduled with no authorized medical use outside clinical trials or special authorised programmes.
Country Details
- Region
- Europe
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Greece maintains a restrictive controlled-substances regime under Law 4139/2013; licensed pharmaceutical psychedelics that have EU marketing authorisations (currently esketamine/Spravato) are available under tight clinical controls, but routine public reimbursement and broad medical access for...
Open access guide →Psychedelic Stakeholders in Greece
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Greece.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Greece.